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Background: Numerous bacterial human growth hormone (hGH) expression methods under conventional
fermentation and induction conditions have been described. Despite significant progress made in this area over the
past several years, production of recombinant hGH by using cellular expression systems still requires further
optimization. Fusion of the ubiquitin (Ub) tag to the hGH protein allowed to increase of the overall efficiency of the
biosynthesis and improve the protein stability. Ub is a protein composed of 76 amino acid residues with a
molecular mass of 8.6 kDa, expressed in all eukaryotes. This protein is an element of the universal protein
modification system, which does not occur in bacteria, and is a useful carrier for heterologous proteins obtained
through expression in Escherichia coli. Purification of Ub-fusion proteins is easier than that of unconjugated
recombinant proteins, and Ub can be removed by deubiquitinating proteases (DUBs or UBPs).
Results and Conclusion: In the present study the UBPD2C protease, a stable UBP1 analog, was produced as a
recombinant protein in E. coli and used for production of recombinant human growth hormone (rhGH). hGH was
expressed as a fusion protein with Ub as a tag. Our findings show that the UBPD2C protease is very effective in
removing the Ub moiety from recombinant Ub-fused hGH. The described approach enables obtaining a considerable
yield of rhGH in a purity required for pharmaceutical products.
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UBP1 protease is a yeast cysteine protease, 809 amino
acids long, which cleaves ubiquitin from proteins fused to
its C-terminus [1], and binds to Ub through an ester bond
during the reaction. The protease activity depends on its
ability to cleave the Ub peptide fused via its C-terminus to
other polypeptides, regardless of the amino acid sequence
of the fused moiety [2].
In some expression systems, proteins of interest are first
expressed as fusions with Ub [3] or its derivatives [4-10], and
then recovered using an Ub-removing enzyme (e.g. UBP1)* Correspondence: wojtowicza@iba.waw.pl
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article, unless otherwise stated.[11,12]. This approach has many advantages, including
improved quality and efficiency of protein expression as
well simplified purification process, which are of great
importance in the industrial production of recombinant
proteins [13-18]. We previously described [19] UBP1
protease deletion and point mutations, which improved
the expression level of the protease in a microbiological
expression system [20].
In technological processes, large quantities of deubi-
quitylating enzyme (DUB) are required for maximum
possible catalytic activity. However, the majority of the
currently available expression protocols does not lead to
efficient expression of DUB, which greatly limits their ap-
plicability, especially in industrial processes. In the pro-
duction of a specific protein for therapeutic application,ed Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
Figure 1 Schematic showing the steps involved in the
purification of the growth hormone. The values obtained for
selected parameters of the process as well as the protein yields
are indicated.
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activity of the enzymes used are important factors. Ac-
cordingly, we have presented various solutions to meet
these requirements [19,20]. Nevertheless, there is still a
need for a method to obtain highly active DUB enzyme
in a gram-scale quantity for the production of bioactive
peptides [4,5,21].
In the present study, we describe the development of
an efficient method for obtaining hGH from bacterial
cells, particularly from Escherichia coli. This method
could yield gram-scale quantities of the protein with ap-
propriate activity for application in the production of
pharmaceutical preparations.
Human growth hormone
22 kDa hGH, also known as somatotropin, is a single
chain polypeptide consisting of total 191 amino acids
[22,23]. It is synthesized and secreted by cells known as
somatotrophs in the anterior pituitary. In the lifetime of
an individual, the highest quantities of growth hormone
are produced during puberty in the anterior lobe or glan-
dular portion of the pituitary [24-28]. hGH is synthesized
as a precursor and released into the blood following
post-translational modifications. The hormone is used in
the treatment of certain forms of dwarfism caused by
hGH deficiencies, in obesity therapy, and in wound and
burn treatment. Clinical trials indicate that hGH helps di-
minish the devastating effects of the hypermetabolic re-
sponse to burn injury especially among children. These
are the reasons why the demand for this hormone is very
high [29-33].
Production of recombinant hGH requires optimization
of vectors used to express the protein in those heterol-
ogous hosts. A series of methods have been designed
[8,34-39]. A generic expression vector features promoter
sequences facilitating transcription and translation as
well as sequences ensuring the stability of the synthesized
protein. The vector described in this study contains
strong promoters that enable efficient synthesis and
accumulation of 30% or more of the targeted recombinant
proteins among the total cellular proteins. In this study,
we have reported the cloning, expression, refolding, and
purification of hGH.
Results and discussion
The Ub tag was used to obtain a mature form of hGH
Ub, the best-known short protein, was used as the tag in
this study. The use of Ub to enhance the levels of protein
expression has been reported previously [4,13,14,40-43].
In the present study, efficient expression of the Ub::hGH
fusion gene in E. coli strains was achieved, and the
UBPD2C analog of the UBP1 protease was used to cleave
the Ub moiety from the N-terminus of the hGH. The hy-
brid polypeptide gene was cloned into several expressionvectors such as pIGAL1, pIGDM1, pIGRKAN, and pIG
MS31KAN. The resulting plasmids pIGDMKUH, pIG
ALUH, pIGALUHM, pIGRKKhGH, and pIGMS31PRH
were used to transform E. coli strains DH5α and NM522.
The E. coli DH5α cells were found to be most suitable with
regard to the expression level of this fusion gene and the
protein purification process. We used several vectors to de-
termine the most suitable one, and the differences between
them have been described in the Materials and methods
section. The above-mentioned expression vectors with
constitutive promoters pms or P1, P2 and terminators T1,
T2 and pms (in appropriate combinations) were used. All
of the constructed E. coli strains carried one of the fol-
lowing plasmids: pIGDMKUH, pIGALUH, pIGALUHM,
pIGRKKhGH, or pIGMS31PRH, and were tested accord-
ing to the procedure briefly presented in Figure 1.
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workflow after harvest of the inclusion bodies: purifica-
tion of Ub::hGH by chromatography on SP Sepharose FF
column, renaturation, protein precipitation and cleavage
of Ub from Ub::hGH fusion protein. Purification of hGH
was performed on Phenyl Sepharose FF column and
then the protein was concentrated on Q Sepharose FF
column. The purity of the preparations at each stage of
purification was monitored via SDS-PAGE (Figures 2
and 3).
Ub::hGH cleavage by UBPD2C-the UBP1 analog
The time course of Ub::hGH fusion protein digestion by
the UBP1 protease analog was analyzed. Aliquots of theFigure 2 SDS-PAGE of the growth hormone samples from
successive purification stages. (A) M, low molecular weight (LMW)
protein marker (94, 67, 43, 30, 20.1, and 14.4 kDa); 1, the protein
dissolved in DRCI buffer; 2, peak I obtained after purification on
DEAE Sepharose FF column; 3, peak I obtained after purification on
SP Sepharose FF column; 4, protein after renaturation; 5, sample
after ammonium sulfate precipitation. (B) M, low molecular weight
(LMW) protein marker (94, 67, 43, 30, 20.1, and 14.4 kDa); 1, growth
hormone European standard; 2, Phenyl Sepharose FF column entry;
3, fraction I obtained after purification on Phenyl Sepharose FF
column; 4, fraction II obtained after purification on Phenyl Sepharose
FF column; 5, fraction III obtained after purification on Phenyl
Sepharose FF column.
Figure 3 SDS-PAGE of Ub::hGH fusion protein cleaved by UBPD2C
protease: M, low molecular weight (LMW) protein marker (94, 67,
43, 30, 20.1, and 14.4 kDa); 1, 10-min digestion; 2, 15-min
digestion; 3 and 7, 30-min digestion; 4, 40-min digestion; 5,
50-min digestion; 6, 60-min digestion; 8, standard Ub::hGH.reaction mixture were collected at different time points
and resolved by SDS-PAGE (Figure 3). It can be clearly
seen from the figure that most of the Ub:hGH was con-
verted to hGH already after 10 min. The reaction pro-
ceeds up to 40 min. From that point the intensity of the
Ub::hGH band does not change indicating termination
of the cleavage.
The stability of the UBPD2C enzyme prepared in an
earlier study [19] was further investigated. The UBP1
protease analog was incubated for 22 h at temperatures
of 4°C, 20°C, 25°C and 37°C, respectively. Subsequently,
each of these test preparations was used for digesting
the Ub::hGH fusion protein under the conditions de-
scribed in the Materials and methods section. Aliquots
of the samples collected at different time points were an-
alyzed by SDS-PAGE. As shown in Figure 4, theFigure 4 SDS-PAGE analysis of the UBPD2C activity after
incubation for 22 h at temperatures of 4°C, 20°C, 25°C and 37°C.
1, 6 Ub::hGH undigested; 2, incubated at 4°C; 3, incubated at 20°C; 4,
incubated at 25°C; 5, incubated at 37°C; M, low molecular weight
standard (kDa).
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tested (Figure 4).
Furthermore, the stability of the purified UBP1 analog
protease was also tested by storing aliquots of the samples
at 20°C, 4°C, -4°C and -20°C for 25 weeks. Subsequently,
standard digestion procedure using the Ub::hGH purified
substrate was carried out and the extent of cleavage
was assessed by SDS-PAGE, followed by densitometric
quantification of the reaction products (GelScan v.
1.45). The results of this analysis, shown in Figure 5,
clearly demonstrated that UBPD2C enzyme can be
stored for 25 weeks at -20°C. If stored at 4°C it is com-
pletely inactivated after 2 weeks and at -4°C after
3 weeks. Incubation of the protease at 20°C for three
days allowed to retain 50% of its activity. After 1 week
in this temperature it became completely inactivated.
Protease stored at -70°C remained active for 25 weeks
(data not shown). The enzyme is capable working in a
wide range of pH (from pH 10.0 to pH 6.0) and
temperature (from 15°C to 50°C) (data not shown).
Final preparations of the hGH purified from the five
tested E. coli strains were analyzed by high-performance
liquid chromatography (HPLC) using the method de-
scribed in the European Pharmacopoeia (5th Edition,
2005) [44]. Accordingly, E. coli DH5α cells carrying the
pIGDMKUH plasmid were found to be the best con-
struct for obtaining hGH. The hGH preparation ob-
tained from this strain and purified according to the
method described earlier exhibited approximately 92.2%
purity, thus fulfilling the specifications/conditions re-
quired by United States Pharmacopeial Convention [45]
and European Pharmacopoeia (7th Edition, 2010) [44]
(Table 1). Accordingly, in order to monitor the size of
molecules present in the Ub::hGH UBPD2C digest and
hGH after Phenlyl Sepharose FF Column, size exclusionFigure 5 Stability of UBPD2C protease. Stability of UBP1 protease measu
or -20°C. The first measurement of UBP1 protease activity incubated at +chromatography (SEC) was performed (data not shown,
please refer to the Figure 1 in the manuscript, showing
the steps involved in the purification of the growth hor-
mone). The protein purity analysis allowed to observe a
significant improvement in hGH purity by removal of
high and low molecular weight impurities present in the
digest.
Analysis of the stability of various hGH expression
constructs in E. coli DH5α cultures grown in an antibiotic-
free LB medium
Stability experiments were conducted according to the
above-described method using the E. coli DH5α host
strain with various expression vectors: pIGMS31PRH,
pIGRKKhGH, pIGDMKUH, pIGALUH, pIGALUHM.
SDS-PAGE and phase contrast microscopy revealed
that the most stable plasmids used for the transform-
ation of E. coli DH5α cells was pIGDMKUH. The plas-
mid was found to remain stable through 80 generations
(four passages) in antibiotic-free cultures (Figure 6). This
finding is important for the use of the protein in the
pharmaceutical industry.
Production of hGH through fermentation using organ-
isms transformed by recombinant hGH expression con-
structs requires optimization of vectors used to express
the proteins of interest in those heterologous hosts. A
generic expression vector features promoter sequences
facilitating transcription and translation as well as se-
quences ensuring the stability of the synthesized protein.
The vectors described in this study contained strong
promoters that could direct efficient synthesis and accu-
mulation of 30% or more of recombinant proteins
among the total cellular proteins. Each construct was
different with respect to the kind of promoter used or
its orientation or transcription terminator or resistancered every week after incubation of this enzyme at +20°C, +4°C, -4°C
20°C followed after 3 days.
Table 1 Results of culturing, isolation of inclusion bodies, and chromatographic purification of hGH from E. coli DH5α
cells carrying the pIGDMKUH plasmid
Phase – Ub/hGH Volume (ml) Protein
(mg/ml) (mg) (%)
Dissolved inclusion bodies 200 2.2 443.3 (100)
DEAE Column entry 200 2.2 443.3 (100)
Sepharose
Fast Flow Fraction 184 1.32 242.8 (54.7)
Column
SP Column entry 184 1.32 242.8 (54.7)
Sepharose
Fast Flow Fraction 184 1.25 230 (51.8)
Column
Protein after renaturation 1680 0.14 230 (51.8)
Protein after ammonium sulfate precipitation to 80% saturation 50 2.85 142.5 (32.1)
Phase – hGH Volume (ml) Protein HPLC purity (%)
(mg/ml) (mg) (%)
Phenyl Column entry 64 1.73 110.7 (24.9) 50
Sepharose
Fast Flow Fractions 50 0.85 42.4 (9.56) 91.8
Column
Q Column load 50 0.85 42.4 (9.56) 91.8
Sepharose
Fast Flow Fractions 10 4.02 40.2 (9.06) 92.2
Column
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selection of one final vector construct enabling most ef-
ficient recombinant hGH expression.
In many cases the overall yield of biologically active
protein is very low, and the methods of purification
hGH are often not efficient or time-consuming. An al-
ternative approach that has been developed involve
complete solubilization and purification of rhGH producedFigure 6 SDS-PAGE assessment of the stability of the pIGDMKUH plas
low molecular weight standard (94, 67, 43, 30, 20.1, and 14.4 kDa); 1, 1st pa
antibiotic pressure; 3, 3rd passage of culture with antibiotic pressure; 4, 4th
control; 6, 1st passage of culture without antibiotic pressure; 7, 2nd passage
without antibiotic pressure; 9, 4th passage of culture without antibiotic presin E. coli. [34]. Kim et al described obtaining of hGH and
His-hGH expression by inducing IPTG and purifying them
on the Ni-NTA column. The other work [46] described
seven N-terminal fusion partners His6, Trx, GST, b’ and a’
domain of PDIb’ a’, NusA, PDI for soluble overexpression
of hGH in E. coli. To cleave the tag proteins from fused
hGH, the TEVrs protease was used. The tobacco etch virus
recognition site ENLYFQ/G was placed at the N-terminusmid in E. coli DH5α cells. Every passage was cultured for 18 h. M,
ssage of culture with antibiotic pressure; 2, 2nd passage of culture with
passage of culture with antibiotic pressure; 5, purified Ub::hGH as
of culture without antibiotic pressure; 8, 3rd passage of culture
sure.
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rather than amino acids. We tried to obtain hGH with a na-
tive growth hormone sequence for medical/pharmaceutical
application.
In addition to the above-mentioned analyses, HPLC
purification, sequencing of the N-terminus (15 amino acid
residues; performed at Biocenter Kraków), and mass spec-
trometry of the purified preparation were performed to
confirm that the protein is hGH.
Biological activity of rhGH
To determine the biological activity of the obtained rhGH,
the protein was allowed to stimulate mitosis, and then
tetrazolium salt (MTT) was added to determine the num-
ber of live cells. In this method, active mitochondrial dehy-
drogenases in the live cells changed the yellow color of the
MTT to a purple product of formazan with a concentration
proportional to the number of live cells.
This method allowed the examination of the biological
activity of the rhGH preparation, and confirmed that
proper tertiary structure of the protein had been obtained.
The calculated biological activity of the preparation was
4.4 IU/mg and that of the somatotropin standard was
2.0 IU/mg. The rhGH protein purified under our condi-
tions retained its biological activity at the comparable level
to that of control hGH. In contrast, no growth stimulation
was observed with BSA, which was used as a negative
control (Figure 7).
Once satisfactory yield of purified hGH was obtained
from 1 l of bacterial culture, the process was further scaled-
up and the growth hormone was produced on a large scale
(data not shown). Usage of 150 liter fermentor enabled to
achieve the production capacity of 250 g per year.Figure 7 Results of the measured biological activity of the prepared r
μQuant Bio-Tek Instruments. (■) control hGH (somatotropin) curve; (♦) c
and (▲) BSA at the indicated concentration.Conclusions
The purpose of this study was to develop an efficient
method for obtaining recombinant hGH from E. coli.
We showed that the strains of E. coli, transformed with
expression plasmids carrying the Ub-growth hormone
gene, yielded satisfactory expression of the Ub-growth
hormone protein in LB medium. In each case, most of
the Ub-growth hormone fusion protein was produced in
the inclusion bodies. The efficiency of protein expression
was found to be sufficiently high, enabling the developed
strains of E. coli to be used for industrial-scale produc-
tion of hGH (220 mg of inclusion bodies/1 l of culture).
This method could facilitate the production of relatively
large quantities of the protein with appropriate quality
(purity: 92.2%) and activity (4.4 IU/mg while the stand-
ard reached 2.0 IU/mg) and application in pharmaceut-
ical industry.
Furthermore, another purpose of this study was to es-
tablish a protocol for growth hormone purification, in
particular, the renaturation conditions. Accordingly, it
was found that the UBP1 protease analog is a flexible
tool that may be successfully used in experimental re-
search as well as in the manufacture of recombinant
proteins.
To summarize, the use of the above-mentioned system
(expression of the final substrate in the form of Ub::hGH
fusion protein and the use of UBP1 analog protease for
deubiquitination), exploiting a highly specific and stable
protease allows retrieving the required protein with high
yield. 20 mg of the purified hGH was obtained from 1 l
of bacterial culture. These properties make it suitable for
a large-scale production in the pharmaceutical industry.
Moreover, it must be noted that the E. coli DH5α strainhGH obtained with the use of KC Junior program in ELISA
urve for absorbance vs. rhGH protein concentration in the preparation
Table 3 Bacterial strains used in this study
Strains Genotype Source
E. coli NM522 F‾ proA + B + lacIq Δ(lacZ)M15/Δ(lac-proAB)
glnV thi-1 Δ(hsdS-mcrB)5
Stratagene
E. coli DH5α F‾, Φ80dlacZΔM15Δ(lacZYA-argF)U169, deoR,
recA1, endA1, hsdR17(rK- mK+), supE44, λ–,
thi-1, gyrA96, relA1
Novagen
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struct, which remained stable and facilitated bacterial
growth in the absence of any antibiotic.
Materials and methods
Primers, plasmids, and bacterial strains
The UBPD2C protease gene was obtained as described
previously [19,20], [47]. The Ub::hGH fusion gene was
cloned into plasmid pIGCMST derivative [48] using re-
striction enzymes, NdeI and SalI. The recombinant plas-
mid was named pIGCMUHGH and was deposited in
GenBank (Accession No. HQ845201) [49].
The pIGCMUHGH plasmid was used as a template
for PCR. The hGHubF and hGHubF primers were used
(Table 2) to amplify the Ub::hGH sequence. The ampli-
fied 450-bp DNA fragment was purified using a DNA
gel extraction kit (A&A Biotechnology, Gdansk, Poland),
and was digested with NdeI and SalI and subcloned into
pIGMS31KAN, pIGRKKAN, pIGDMKUH, pIGALUH,
and pIGALUHM expression vectors. Each of the ob-
tained plasmids was sequenced to confirm the identity
of the DNA sequence. Subsequently, these plasmids
were transformed into E. coli strain NM522. The geno-
types of the bacterial strains used in this study are listed
in Table 3. The strains were grown in Luria-Bertani (LB)
medium as described previously [50].
Construction of expression vectors
pms promoter and deo P1 P2 promoter
The pms promoter was isolated from a plasmid present
in a clinical strain of Klebsiella pneumonia (GenBank
Accession No. AY543071) [49,50]. It is a strong, consti-
tutive promoter (Patent PL 213561). The sequence of
the deo P1P2 promoter/operator region is known and
the entire deo P1P2 promoter region is approximately
760 bp long, with the two promoters being separated by
a distance of about 600 bp. Expression of a gene product
under deo P2-driven transcription is very low in the
presence of glucose and very high in the presence of
other energy producing sources. Initiations from P1 are
negatively controlled by the deoR repressor, the inducer
being deoxyribose-5-phosphate (deoxyribose-5-P). Initia-
tions from P2 depend on the cyclic AMP/cyclic AMPTable 2 Nucleotide sequences of primers used for PCR
and construction of Ub::hGH fusion gene









58 R.SalIreceptor protein complex (cAMP/CRP) and are nega-
tively controlled by the cytR repressor, the inducer being
cytidine [51].
pIGMS31KAN plasmid
The promoter sequence of retron Ec86 and its following
transcription terminator sequence [52] were inserted
into pIGMS31KAN plasmid. The resulting pIGMS31PR
plasmid was used to clone the Ub::hGH fusion gene
(Figure 8).
pIGRKKAN plasmid
P1 and P2 deo operon of E. coli strain K-12 promoters,
and the gene encoding the fusion protein composed of
synthetic Ub and the gene growth hormone in R.NdeI
and R.SalI restriction sites were cloned into pIGRKKAN
plasmid, which was isolated from K. pneumonia strain
287-w. The restriction map of the recombinant plasmid
is presented in Figure 8.
pIGDMKUH plasmid
The pIGDMKUH plasmid was derived from pIGDM1
plasmid (GenBank Accession No. AF014880) [49]. The
length of the pIGDMKUH plasmid was 3887 bp and
contained the pms promoter and T1, T2 transcription
terminators [53]. The synthetic Ub::hGH fusion gene
was cloned into R.NdeI and R.SalI sites (Figure 8).
pIGALUH and pIGALUHM plasmids
The pIGALUH and pIGALUHM plasmids were derived
from pIGAL1 plasmid (GenBank Accession No. AY424310).
The synthetic Ub::hGH fusion genes were cloned into the
pIGALUH and pIGALUHM plasmids. The pIGALUH plas-
mid contained the ampicillin resistance gene, pms promoter,
and terminator sequences, while the pIGALUHM plasmid
contained the ampicillin resistance gene, pms promoter in
reverse orientation, as well as an additional transcription ter-
minator located upstream of the pms promoter (Figure 8).
Creating bacterial glycerol stocks for long-term storage of
plasmids
The method of preparing bacterial stocks is critical for
maintaining efficient expression and plasmid stability in
host cells. One bacterial colony was inoculated into 3 ml
Figure 8 Schematic representation of the expression vectors A-pIGRKKAN, B-pIGMS31KAN, C-pIGALUHM, D-pIGALUH and E-pIGDMKUH.
hGH was expressed as a fusion protein with the Ub tag. The restriction enzyme sites used to clone the Ub::hGH gene are indicated.
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was incubated under shaking for 4 h at 37°C, and then
transferred into 20 ml of LB medium with antibiotic and
again incubated under shaking at 37°C until the optical
density measured at 600 nm (OD600) reached ≈ 1. The cul-
ture was subsequently aliquoted into sterile Eppendorf
tubes (0.5 ml/tube) and 0.5 ml of 40% glycerol was added
to each tube. The bacterial stocks were stored at −70°C.
Later, 0.5 ml of the stock was added to 1 l of LB
medium, and 200 ml of the LB medium supplemented
with 200 μl of ampicillin (100 μg/ml) or 200 μl of
kanamycin (50 μg/ml) and 100 μl of the inoculate was
added to a 500-ml flask. The culture was incubated in
a rotary shaker at 160 rpm and 37°C for 18 h, and then
centrifuged at 6000 rpm for 5 min at 4°C. The obtainedbacterial cell pellet was processed as described in the
subsequent section.
Purification of Ub::hGH and cleavage of the fusion protein
by deubiquitinating UBPD2C
Isolation of inclusion bodies
Wet cell biomass of 5–7 g, obtained from 1 l of culture,
was suspended in 100 ml of Buffer C (50 mM Tris HCl,
0.5 M NaCl, and 5 mM β-mercaptoethanol; pH 7.5), and
lysozyme was added to a final concentration of 0.43 mg/ml.
The suspension was incubated for 35 min at 20°C. Then,
Triton X-100 was added to a final concentration of 1%
and the mixture was sonicated. Subsequently, phenyl-
methylsulfonyl fluoride (PMSF) was added to a final
concentration of 1 mM and then glycerol followed in a
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cell suspension. The mixture was centrifuged at
8000 rpm for 20 min at 20°C. The precipitate contain-
ing inclusion bodies was suspended in 100 ml of CT buffer
(50 mM Tris HCl, 0.5 M NaCl, 5 mM β-mercaptoethanol,
and 1% Triton X-100; pH 7.5) and sonicated for 10 min on
ice, as previously described [50]. After centrifugation at
8000 rpm for 20 min, the precipitate was suspended in
100 ml of phosphate buffered saline (PBS) with 1% Triton
X-100 and sonicated [50]. The precipitate was centrifuged
again and suspended in 100 ml of PBS with 2 M urea, soni-
cated as reported [50], and centrifuged for another time to
obtain the inclusion bodies. The yield of inclusion bodies
was between 0.7 and 1.2 g/l of culture.
The inclusion bodies were dissolved in DRCI buffer
(6–8 M urea, 50 mM phosphate buffer, and 5 mM β-
mercaptoethanol; pH 12). The solution was cleared by
centrifugation, its pH was adjusted to 7.0 with concen-
trated phosphoric acid, and was subsequently loaded
onto DEAE Sepharose fast flow (FF) column (approxi-
mately 100 ml; GE Healthcare Life Sciences) equilibrated
with 6–8 M urea and 20 mM phosphate buffer at
pH 7.0. The flow through material, containing the Ub::
hGH protein, was collected and the fusion protein was
loaded onto SP Sepharose FF column.
SP Sepharose FF column
The pooled Ub::hGH peak fractions from the DEAE
Sepharose FF column were directly loaded onto a 30-ml
column filled with SP Sepharose FF (Amersham Phar-
macia Biotech AB) equilibrated with 6–8 M urea and
20 mM phosphate buffer at pH 7.0. The flow through
material, containing the Ub::hGH protein, was collected
and renatured. Separation on this column was not ne-
cessary if the Ub::hGH protein yield from the DEAE col-
umn was about 70%.
Renaturation
Ub::hGH in fractions from the SP Sepharose FF column
was renatured by approximately 10-fold dilution in BR
buffer (20 mM phosphate buffer pH 7.0, 50 mM NaCl)
to a concentration of 0.09–0.15 mg/ml protein and then
incubated for 1 h at room temperature.
Ammonium sulfate precipitation
After renaturation, the fusion protein was precipitated
by adding ammonium sulfate to 80% saturation at 4°C
under constant stirring. The samples were centrifuged at
12000 rpm for 15 min at 4°C. The pellet was suspended
in 1/40th of the pre-centrifugation sample volume (ap-
proximately 50 ml) of 20 mM phosphate buffer (pH 7.5)
and 0.5 M NaCl, and then centrifuged at 12000 rpm for
15 min at 4°C.Cleavage of Ub::hGH fusion protein using UBPDC, UBPD2C
protease
The supernatant (protein in 20 mM phosphate buffer
(pH 7.5) + 0.5 M NaCl) was incubated with appropriate
DUB preparations to cleave the Ub moiety from the
growth hormone polypeptide. The reaction was per-
formed at 37°C for 1 h (1 μl of UBPD2C 60 μg of pro-
tein; 1 μl of UBPDC – 14 μg of protein). Then, the
sample was centrifuged at 12000 rpm for 15 min at 4°C.
The supernatant was fractionated by chromatography on
Phenyl Sepharose FF resin. The purification process of
UBPD2C and UBPDC proteases has been described else-
where [19,47].Phenyl Sepharose FF column
Approximately 20 ml of Phenyl Sepharose FF column
(GE Healthcare Life Sciences) was equilibrated with
0.5 M NaCl and 20 mM phosphate buffer (pH 7.0). The
hGH protein was eluted with a 3 mM phosphate buffer
at pH 7.0–9.0. The fractions containing the growth hor-
mone were collected, and the protein solution was ad-
justed to pH 7.0 using concentrated phosphoric acid and
stored at 4°C.Q Sepharose FF column
The growth hormone fractions from Phenyl Sepharose
FF column were concentrated on a 10-ml Q Sepharose
FF column (Amersham Pharmacia Biotech AB). The car-
rier was equilibrated with 20 mM phosphate buffer at
pH 7.5, transferred to the column, and eluted with a lin-
ear gradient of 0.5 M NaCl in 20 mM phosphate buffer
(growth hormone containing fractions were eluted at
0.25 M NaCl).Storage
The purified growth hormone was transferred into
3.1 mM Na2HPO4 (pH 7.0; by hydrophobic interaction
chromatography, carrier: Phenyl Sepharose FF, isocratic
distribution) for storage at 4°C.Verification of plasmid stability in cultures grown in LB
medium without antibiotic
One stock was inoculated into 50 ml of antibiotic-free
LB medium. The culture was incubated under shaking at
37°C until an OD600 of ~1 was reached. Subsequently,
1 ml of the culture was used for successive passages.
Four passages were carried out for each culture for 18 h,
and 1-ml samples were collected to obtain bacterial ly-
sates. The Ub::hGH gene expression was verified in the
host cells. The experiment was repeated four times inde-
pendent of the transformation phase, and the accuracy
of the results was confirmed.
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Quantitative analyses of the proteins Ub::hGH, Ub, and
hGH were performed by staining with 0.05% Coomassie
Brilliant Blue R250 and obtaining electropherograms using
the software package Scangel v. 1.45 program (Kucharczyk
T.E., Warsaw, Poland). For destaining, the gels were incu-
bated in the same solution without the dye.
Biological activity assay method
The hGH biological activity assay in the Nb-2 rat cell
line was carried out as described previously [51,54-56].
Nb-2 is a prolactin-related cell line sensitive to hGH
(somatotropin; European Collection of Cell Cultures
(ECACC)). The Nb-2 cells were prepared for the hGH
assay as described by Tanaka et al. [57]. After a 24-h
incubation period, the cells were suspended at a con-
centration of 1 × 105 cell/ml in RPMI-1640 medium
containing 10% horse serum, glutamine, antibiotic, and
2-mercaptoethanol. Subsequently, 100 μl of the sus-
pension were added to each well of a 96-well cell cul-
ture plate, flat bottom (Nunc).
hGH standard solution
Somatotropin (2.0 IU/mg protein specific activity (SIGMA
S-4776)) was used as the standard for hGH biological ac-
tivity assay. The somatotropin solution was distributed
onto a plate with Nb-2 cells so that its concentrations on
the plate were 0.004, 0.008, 0.015, 0.03, 0.06, 0.12, 0.265,
0.53, 0.8, 1.07, and 1.33 ng/ml. Six replicates were assayed
for each somatotropin concentration.
Preparation of dilutions of the test hGH preparation
The growth hormone protein concentration in the test
preparation was assayed at a wavelength of 280 nm,
considering the amount of tyrosine, tryptophan, and
cysteine in the hGH. Solutions of the growth hormone
preparation were distributed onto a plate with Nb-2
cells in six replicates. The scheme of solutions distri-
bution and their concentrations were similar to those
employed for somatotropin, the commercial marker of
hGH.
Absorbance reading
The plates were incubated for 72 h (37°C, 5% CO2). Sub-
sequently, 15 μl of MTT solution (5 mg MTT/1 ml of
PBS) were added to each well, and the plates were incu-
bated for 3 h at 37°C. Then, 60 μl of lysis buffer (10%
Triton X-100, 0.2 N HCl, and 20% isopropanol) were
added to each well and gently stirred. After that, 50 μl of
DMSO were added and the plates were incubated for
0.5 h at 37°C. The absorbance was read with an ELISA
plate reader (μQuant Bio-Tek Instruments) at two wave-
lengths: 585 and 655 nm. The somatotropin standardcurves and hGH activity were determined using the KC
Junior software program.
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